Pfiz­er and My­ovant’s en­dometrio­sis pain drug Myfem­bree gets an­oth­er FDA nod

Af­ter months of de­lay in its de­ci­sion, the FDA has giv­en a green light to Pfiz­er and My­ovant’s drug Myfem­bree for pain re­lat­ed en­dometrio­sis, a gy­ne­co­log­i­cal con­di­tion as­so­ci­at­ed with mod­er­ate to se­vere pain, mak­ing it the drug’s sec­ond in­di­ca­tion ap­proval.

The FDA had ear­li­er de­layed its de­ci­sion to re­view ad­di­tion­al da­ta it had re­quest­ed from the com­pa­nies re­gard­ing bone min­er­al den­si­ty. The reg­u­la­tors had “iden­ti­fied de­fi­cien­cies that pre­clude dis­cus­sion of la­bel­ing and/or post-mar­ket­ing re­quire­ments and com­mit­ment at this time,” the com­pa­nies had said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER